![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.biospectrumasia.com/news/25/24084/nxera-pharma-inks-deal-with-handok-to-distribute-pivlaz-in-south-korea.html
https://www.globenewswire.com/news-release/2024/04/14/2862478/0/en/Nxera-Pharma-Announces-Exclusive-Supply-and-Distribution-Agreement-with-Handok-for-PIVLAZ-in-South-Korea.html
https://www.globenewswire.com//news-release/2023/12/07/2792220/0/en/Sosei-Group-Announces-Marketing-Approval-for-PIVLAZ-clazosentan-sodium-150-mg-in-South-Korea.html
https://www.globenewswire.com/news-release/2023/02/06/2601762/0/de/Idorsia-announces-th[…]patients-following-aneurysmal-subarachnoid-hemorrhage.html
https://www.globenewswire.com/news-release/2022/04/20/2425136/0/de/PIVLAZ-clazosentan-Idorsia-s-first-commercial-product-now-available-for-patients-in-Japan.html
https://www.globenewswire.com/news-release/2022/04/04/2415246/0/de/The-Journal-of-Neurosurgery-reports-impact-of-clazosentan-on-cerebral-vasospasm-related-morbidity-and-all-cause-mortality-after-aneurysmal-subarachnoid-hemorrhage.html
https://www.globenewswire.com/news-release/2022/01/20/2369799/0/en/Idorsia-receives-Japanese-PMDA-approval-of-PIVLAZ-clazosentan-sodium-150-mg.html
https://www.globenewswire.com/news-release/2021/03/01/2183851/0/en/Idorsia-submits-NDA-for-clazosentan-to-Japanese-PMDA.html#:~:text=Idorsia%20Ltd%20(SIX%3A%20IDIA),vasospasm%2Drelated%20cerebral%20infarction%20and
https://www.globenewswire.com/news-release/2020/11/23/2132075/0/en/Idorsia-announces-positive-results-of-the-two-Japanese-registration-studies-with-clazosentan.html#:~:text=Idorsia%20announces%20positive%20results%20of%20the%20two%20Japanese%20registration%20studies%20with%20clazosentan,-Email%20Print%20Friendly&text=Clazosentan%20demonstrates%20significant%20reduction%20of%20all%2Dcause%20morbidity%20and%20mortality,of%20data%20from%20both%20studies.